- Conditions
- Schizophrenia Spectrum Disorder
- Interventions
- TMS, sham
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 55
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- MMFS-202-302, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Dietary Supplement: Pregnenolone, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Schizophrenia
- Interventions
- rasagiline (Pharmacodynamics), Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
- Conditions
- Schizophrenia
- Interventions
- Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Schizophrenia
- Interventions
- 1 Hz rTMS, 10 Hz rTMS
- Device
- Lead sponsor
- Seton Healthcare Family
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Pravastatin
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- PF-03463275, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 37
- States / cities
- Cerritos, California • Chula Vista, California • Escondido, California + 26 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, RO5545965
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • St Louis, Missouri
- Conditions
- Schizophrenia
- Interventions
- Oxytocin, Galantamine, Placebo-Oxytocin, Placebo-Galantamine
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
- Conditions
- Schizophrenia
- Interventions
- Folate, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
- Interventions
- N-acetylcysteine, Treatment as Usual
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Schizophrenia
- Interventions
- Modafinil, Placebo
- Drug
- Lead sponsor
- Veterans Medical Research Foundation
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Schizophrenia
- Interventions
- Digital therapeutic (CT-155)
- Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 31
- States / cities
- Imperial, California • La Jolla, California • Oceanside, California + 25 more
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders
- Interventions
- risperidone, sertraline-primary
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia
- Interventions
- Oral Glucose Tolerance Test (OGTT)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia
- Conditions
- Schizophrenia
- Interventions
- modafinil, Placebo
- Drug
- Lead sponsor
- North Suffolk Mental Health Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- RO6889450, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 28
- States / cities
- Bellflower, California • Garden Grove, California • Glendale, California + 23 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- d-cycloserine, glycine, placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
- Conditions
- Negative Symptoms of Schizophrenia
- Interventions
- Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
- Drug
- Lead sponsor
- Minerva Neurosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more
- Conditions
- Schizophrenia, Serious Mental Illness
- Interventions
- Engaging in Community Roles and Experiences (ENCoRE), Health & Wellness (H&W)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia
- Interventions
- Luvadaxistat, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Garden Grove, California • Lemon Grove, California • Los Angeles, California + 13 more
- Conditions
- Schizophrenia
- Interventions
- Cognitive Enhancement Therapy, Enriched Supportive Therapy
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- CBSST-CCT, Goal focused supportive contact
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California